Impact of MDM2 SNP309 on Leukemia and Lymphoma
Author Information
Author(s): Sean M. Post, Vinod Pant, Hussein Abbas, Alfonso Quintás-Cardama
Primary Institution: University of Texas, M.D. Anderson Cancer Center
Hypothesis
Does the MDM2 SNP309 allele influence cancer risk and treatment outcomes in leukemia and lymphoma?
Conclusion
The MDM2 SNP309G allele is associated with earlier onset of childhood ALL and increased risk of de novo AML, but its impact on CLL is less clear.
Supporting Evidence
- The MDM2 SNP309G allele is linked to earlier onset of childhood ALL in certain ethnic groups.
- Patients with the MDM2 SNP309G allele may have a higher risk of developing de novo AML.
- Conflicting results exist regarding the impact of MDM2 SNP309 on CLL outcomes.
Takeaway
Some people have a gene change that might make them get certain blood cancers earlier or more often, but it's complicated and depends on other factors.
Methodology
The study reviews various retrospective analyses and discusses the impact of the MDM2 SNP309 allele on leukemia and lymphoma.
Potential Biases
Retrospective nature of studies may introduce biases related to patient selection and genetic diversity.
Limitations
The studies reviewed are mostly retrospective, which can introduce biases, and they involve diverse patient populations that complicate interpretations.
Participant Demographics
The studies include patients from various ethnic backgrounds, including Ashkenazi Jews, Caucasians, and African-Americans.
Want to read the original?
Access the complete publication on the publisher's website